8-K filing — Zura Bio Ltd (ZURA)
Filed: 2026-08-17 AccNo: 0001104659-26-097526 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Filed: 2026-08-11 AccNo: 0001855644-26-000007 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-17 AccNo: 0001104659-26-097526 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarWedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.
Read original at benzingaGuggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.
Read original at benzingaZura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 23.53 percent decrease over losses of $(0.17) per share from the same
Read original at benzinga